AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32653721 — intervention group
Group type: COMPARATOR
Intervention: Standard in‐person OOPP
Number of subjects: 94
Study 35255091 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based physiotherapy program (3 days a week, supervised for 4 weeks, tele-supervised for 4 weeks)
Number of subjects: 30
Study 35255091 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control Group)
Number of subjects: 30
Study 32931984 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive management
Number of subjects: 335
Study 32594451 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine 200 mg OD
Number of subjects: 304
Study 32594451 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine 300 mg OD
Number of subjects: 304
Study 32594451 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine 400 mg OD
Number of subjects: 304
Study 32594451 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 304
Study 32594451 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine 200 mg BD
Number of subjects: 304
Study 33404791 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated Patient Outreach (APO) app
Number of subjects: 120
Study 33404791 — intervention group
Group type: COMPARATOR
Intervention: Manual phone calls
Number of subjects: 120
Study 32305572 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 ng/kg LPS intravenous administration
Number of subjects: 24
Study 32305572 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 ng/kg LPS intravenous administration
Number of subjects: 24
Study 32305572 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 33231278 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee joint distraction (KJD)
Number of subjects: 51
Study 33231278 — intervention group
Group type: COMPARATOR
Intervention: High tibial osteotomy (HTO)
Number of subjects: 51
Study 36181990 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (800 IU/day) for 30 months
Number of subjects: 270
Study 34187564 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief weight management intervention delivered at child immunisation appointments
Number of subjects: 0
Study 32880601 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg
Number of subjects: 763
Study 32880601 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy
Number of subjects: 763
Study 32880601 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 763
Study 32880601 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 763
Study 34319940 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrulline-Malate (8 g CM + 12 g dextrose)
Number of subjects: 19
Study 34319940 — intervention group
Group type: COMPARATOR
Intervention: Placebo (12 g dextrose)
Number of subjects: 19
Study 33864847 — intervention group
Group type: EXPERIMENTAL
Intervention: EMPOWER 2 intervention
Number of subjects: 10
Study 36644821 — intervention group
Group type: EXPERIMENTAL
Intervention: Adipose tissue-derived mesenchymal stromal cells (CSCC_ASCs)
Number of subjects: 133
Study 36644821 — intervention group
Group type: COMPARATOR
Intervention: Placebo (isotonic saline)
Number of subjects: 133
Study 32502730 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric compression for 24 hours followed by compression stockings of 18 to 20 mm Hg for 1 week
Number of subjects: 50
Study 32502730 — intervention group
Group type: COMPARATOR
Intervention: No further compression after sclerotherapy
Number of subjects: 50
Study 35432695 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol 400mcg
Number of subjects: 203
Study 35432695 — intervention group
Group type: COMPARATOR
Intervention: Manual vacuum aspiration
Number of subjects: 203
Study 32584834 — intervention group
Group type: EXPERIMENTAL
Intervention: Low household income
Number of subjects: 637
Study 32584834 — intervention group
Group type: EXPERIMENTAL
Intervention: Current employment
Number of subjects: 637
Study 32584834 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer sleeping hours
Number of subjects: 637
Study 32584834 — intervention group
Group type: EXPERIMENTAL
Intervention: Living with a partner
Number of subjects: 637
Study 32584834 — intervention group
Group type: EXPERIMENTAL
Intervention: Being overweight
Number of subjects: 637
Study 32584834 — intervention group
Group type: COMPARATOR
Intervention: Overall resolution rate
Number of subjects: 637
Study 33755862 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Number of subjects: 8
Study 33755862 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-HER2 blockade with trastuzumab plus either pertuzumab or lapatinib
Number of subjects: 8
Study 33755862 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Number of subjects: 8
Study 33755862 — intervention group
Group type: COMPARATOR
Intervention: Trastuzumab emtansine
Number of subjects: 8
Study 33755862 — intervention group
Group type: EXPERIMENTAL
Intervention: MET co-targeting
Number of subjects: 8
Study 35152464 — intervention group
Group type: EXPERIMENTAL
Intervention: MTA
Number of subjects: 164
Study 35152464 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodentine
Number of subjects: 164
Study 35152464 — intervention group
Group type: EXPERIMENTAL
Intervention: TotalFill
Number of subjects: 164
Study 35152464 — intervention group
Group type: COMPARATOR
Intervention: Control (MTA, Biodentine, TotalFill)
Number of subjects: 164
Study 35152464 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 164
Study 34514701 — intervention group
Group type: EXPERIMENTAL
Intervention: Idiopathic granulomatous mastitis with erythema nodosum (EN)
Number of subjects: 86
Study 34514701 — intervention group
Group type: COMPARATOR
Intervention: Idiopathic granulomatous mastitis only (control group)
Number of subjects: 86
Study 35745198 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g/day bovine lactoferrin (bLF) for 3 weeks (T2)
Number of subjects: 25
Study 35745198 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g/day bLF and 2.64 g/day active galactooligosaccharides (GOS) for 3 weeks (T3)
Number of subjects: 25
Study 35745198 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g/day bLF, 2.64 g/day GOS and 20 μg/day vitamin D for 3 weeks (T4)
Number of subjects: 25
Study 35745198 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 25
Study 34604026 — intervention group
Group type: EXPERIMENTAL
Intervention: ReStOre program (exercise training, dietary counselling, and multidisciplinary education)
Number of subjects: 37
Study 34604026 — intervention group
Group type: EXPERIMENTAL
Intervention: ReStOre program
Number of subjects: 37
Study 34604026 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 37
Study 34154913 — intervention group
Group type: COMPARATOR
Intervention: Pre-QI (2017) survey respondents
Number of subjects: 94
Study 34154913 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-QI (2019) survey respondents
Number of subjects: 94
Study 34154913 — intervention group
Group type: EXPERIMENTAL
Intervention: First-time respondents in 2019
Number of subjects: 94
Study 34421257 — intervention group
Group type: EXPERIMENTAL
Intervention: Check pyeloscopic percutaneous nephrolithotomy (CP‐PCNL)
Number of subjects: 100
Study 34421257 — intervention group
Group type: COMPARATOR
Intervention: Conventional percutaneous nephrolithotomy (C‐PCNL)
Number of subjects: 100
Study 33101444 — intervention group
Group type: EXPERIMENTAL
Intervention: Qingshen granules (three times daily for 12 weeks)
Number of subjects: 282
Study 33101444 — intervention group
Group type: COMPARATOR
Intervention: Conventional Western medical therapy (control group)
Number of subjects: 282
Study 35716319 — intervention group
Group type: EXPERIMENTAL
Intervention: DE-089C (long-acting diquafosol ophthalmic solution), administered three times daily for 4 weeks
Number of subjects: 337
Study 35716319 — intervention group
Group type: COMPARATOR
Intervention: Placebo ophthalmic solution, administered three times daily for 4 weeks
Number of subjects: 337
Study 34626550 — intervention group
Group type: EXPERIMENTAL
Intervention: ramucirumab plus paclitaxel
Number of subjects: 440
Study 34626550 — intervention group
Group type: COMPARATOR
Intervention: placebo plus paclitaxel
Number of subjects: 440
Study 33263641 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart failure (HF) patients during active postural maneuver (APM)
Number of subjects: 41
Study 33263641 — intervention group
Group type: COMPARATOR
Intervention: COPD-HF patients during active postural maneuver (APM)
Number of subjects: 41
Study 33263641 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart failure (HF) patients during respiratory sinus arrhythmia maneuver (RSA-M)
Number of subjects: 41
Study 33263641 — intervention group
Group type: COMPARATOR
Intervention: COPD-HF patients during respiratory sinus arrhythmia maneuver (RSA-M)
Number of subjects: 41
Study 35942886 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin-to-skin contact (SSC) for one hour daily from birth until postnatal week five
Number of subjects: 116
Study 35942886 — intervention group
Group type: COMPARATOR
Intervention: Care-as-usual (CAU)
Number of subjects: 116
Study 32783395 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 215
Study 32783395 — intervention group
Group type: COMPARATOR
Intervention: Sulfonylurea
Number of subjects: 215
Study 32783395 — intervention group
Group type: EXPERIMENTAL
Intervention: Ala carriers
Number of subjects: 215
Study 32783395 — intervention group
Group type: COMPARATOR
Intervention: Non-carriers
Number of subjects: 215
Study 32783395 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro12Ala polymorphism
Number of subjects: 215
Study 33248059 — intervention group
Group type: EXPERIMENTAL
Intervention: NSTE-MI
Number of subjects: 665
Study 33248059 — intervention group
Group type: EXPERIMENTAL
Intervention: LBBB-MI
Number of subjects: 665
Study 33248059 — intervention group
Group type: COMPARATOR
Intervention: ECG presentation
Number of subjects: 665
Study 33742266 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Power Training (FPT) program, 12-week duration, 2 sessions per week of 60 minutes each
Number of subjects: 61
Study 33742266 — intervention group
Group type: COMPARATOR
Intervention: Usual activities at senior centers
Number of subjects: 61
Study 33096291 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure therapy + PE‐FMR
Number of subjects: 166
Study 33096291 — intervention group
Group type: COMPARATOR
Intervention: Exposure therapy alone
Number of subjects: 166
Study 33096291 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure therapy + DE
Number of subjects: 166
Study 33096291 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure therapy + PE‐FMR + DE
Number of subjects: 166
Study 36091150 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined (preoperative calcitriol and calcium)
Number of subjects: 172
Study 36091150 — intervention group
Group type: COMPARATOR
Intervention: Control (no preoperative intervention)
Number of subjects: 172
Study 36091150 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium only (preoperative calcium only)
Number of subjects: 172
Study 33082056 — intervention group
Group type: EXPERIMENTAL
Intervention: Low HDL-cholesterol levels (low-HDLc)
Number of subjects: 6588
Study 33082056 — intervention group
Group type: EXPERIMENTAL
Intervention: Atherogenic dyslipidemia (AD)
Number of subjects: 6588
Study 33082056 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular risk factors
Number of subjects: 6588
Study 33082056 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent factors associated with low HDLc
Number of subjects: 6588
Study 33082056 — intervention group
Group type: EXPERIMENTAL
Intervention: Major factors associated with low HDLc and AD
Number of subjects: 6588
Study 35995728 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin
Number of subjects: 299
Study 35995728 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 299
Study 32725475 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified suturing technique (group A)
Number of subjects: 257
Study 32725475 — intervention group
Group type: COMPARATOR
Intervention: Standard technique (group B)
Number of subjects: 257
Study 35706488 — intervention group
Group type: EXPERIMENTAL
Intervention: Active symptom control with oral vinorelbine (ASC + vinorelbine)
Number of subjects: 154
Study 35706488 — intervention group
Group type: COMPARATOR
Intervention: Active symptom control (ASC)
Number of subjects: 154
Study 34506512 — intervention group
Group type: EXPERIMENTAL
Intervention: Flipped classroom
Number of subjects: 137
Study 34506512 — intervention group
Group type: COMPARATOR
Intervention: Lecture
Number of subjects: 137
Study 33431242 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes medication-taking behavior
Number of subjects: 1270
Study 33431242 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication-taking behavior
Number of subjects: 1270
Study 33431242 — intervention group
Group type: EXPERIMENTAL
Intervention: Hurried Communication
Number of subjects: 1270
Study 33431242 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes distress
Number of subjects: 1270
Study 35772139 — intervention group
Group type: EXPERIMENTAL
Intervention: Musicotherapy combined with cognitive behavioral intervention
Number of subjects: 120
Study 35772139 — intervention group
Group type: COMPARATOR
Intervention: Control group (blank control, no intervention)
Number of subjects: 120
Study 34106303 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous pertuzumab and trastuzumab (PH FDC SC)
Number of subjects: 0
Study 34106303 — intervention group
Group type: COMPARATOR
Intervention: Intravenous pertuzumab and trastuzumab
Number of subjects: 0
Study 36351465 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 5 mg daily
Number of subjects: 190
Study 36351465 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190
Study 36351465 — intervention group
Group type: COMPARATOR
Intervention: Fish oil
Number of subjects: 190
Study 36351465 — intervention group
Group type: COMPARATOR
Intervention: Cinnamon
Number of subjects: 190
Study 36351465 — intervention group
Group type: COMPARATOR
Intervention: Garlic
Number of subjects: 190
Study 36351465 — intervention group
Group type: COMPARATOR
Intervention: Turmeric
Number of subjects: 190
Study 36351465 — intervention group
Group type: COMPARATOR
Intervention: Plant sterols
Number of subjects: 190
Study 36351465 — intervention group
Group type: COMPARATOR
Intervention: Red yeast rice
Number of subjects: 190
Study 33412260 — intervention group
Group type: EXPERIMENTAL
Intervention: 74 Gy/37 fractions (Fr)
Number of subjects: 0
Study 33412260 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 Gy/20 Fr
Number of subjects: 0
Study 33412260 — intervention group
Group type: EXPERIMENTAL
Intervention: 57 Gy/19 Fr
Number of subjects: 0
Study 33412260 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclusion of IBD/diverticular disease as a DMF
Number of subjects: 0
Study 33412260 — intervention group
Group type: COMPARATOR
Intervention: No DMF vs DMF models for stool frequency G2+
Number of subjects: 0
Study 33412260 — intervention group
Group type: COMPARATOR
Intervention: No DMF vs DMF models for proctitis G1+
Number of subjects: 0
Study 32725178 — intervention group
Group type: EXPERIMENTAL
Intervention: Improving Pain During Addiction Treatment (ImPAT)
Number of subjects: 510
Study 32725178 — intervention group
Group type: COMPARATOR
Intervention: Supportive Psychoeducational Control (SPC)
Number of subjects: 510
Study 35038412 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac magnetic resonance stress myocardial perfusion imaging (CMR‐MPI)
Number of subjects: 0
Study 35038412 — intervention group
Group type: COMPARATOR
Intervention: No additional functional imaging
Number of subjects: 0
Study 32761160 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan (up to 32 mg once daily)
Number of subjects: 176
Study 32761160 — intervention group
Group type: COMPARATOR
Intervention: Lisinopril (up to 40 mg once daily)
Number of subjects: 176
Study 36175963 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced monitoring and feedback (EMF)
Number of subjects: 72
Study 36175963 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-day workshop
Number of subjects: 72
Study 36175963 — intervention group
Group type: COMPARATOR
Intervention: Internal facilitation
Number of subjects: 72
Study 36175963 — intervention group
Group type: COMPARATOR
Intervention: External facilitation
Number of subjects: 72
Study 34769851 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic gymnastics (80 min/d, 5 d/wk for 8 months)
Number of subjects: 102
Study 34769851 — intervention group
Group type: COMPARATOR
Intervention: Control group (observation)
Number of subjects: 102
Study 34769851 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic gymnastics
Number of subjects: 102
Study 33271502 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-selected condition
Number of subjects: 15
Study 33271502 — intervention group
Group type: COMPARATOR
Intervention: Imposed condition
Number of subjects: 15
Study 33271502 — intervention group
Group type: COMPARATOR
Intervention: Traditional condition
Number of subjects: 15
Study 34152031 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribociclib plus fulvestrant
Number of subjects: 0
Study 34152031 — intervention group
Group type: COMPARATOR
Intervention: Fulvestrant alone (Control)
Number of subjects: 0
Study 33357803 — intervention group
Group type: EXPERIMENTAL
Intervention: Education program and traditional music
Number of subjects: 60
Study 33357803 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study 32727336 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithyroid therapy (thioamides and/or surgical therapy)
Number of subjects: 71
Study 32727336 — intervention group
Group type: COMPARATOR
Intervention: Surgical therapy (group 2, n=9)
Number of subjects: 71
Study 32727336 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy (group 1, n=62)
Number of subjects: 71
Study 32615145 — intervention group
Group type: EXPERIMENTAL
Intervention: Connectedness to Nature (CN) intervention (10 sessions of a family-based programme)
Number of subjects: 241
Study 32615145 — intervention group
Group type: EXPERIMENTAL
Intervention: Connectedness to Nature (CN) intervention
Number of subjects: 241
Study 32615145 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG) receiving only government's health recommendations
Number of subjects: 241
Study 35332374 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive psychology intervention (PPI) with standard care
Number of subjects: 120
Study 35332374 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 120
Study 33902333 — intervention group
Group type: EXPERIMENTAL
Intervention: UC with acupuncture
Number of subjects: 11
Study 33902333 — intervention group
Group type: EXPERIMENTAL
Intervention: UC with pain counseling
Number of subjects: 11
Study 33902333 — intervention group
Group type: EXPERIMENTAL
Intervention: UC with acupuncture and pain counseling
Number of subjects: 11
Study 33902333 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 11
Study 35477992 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose unfractionated heparin (UFH)
Number of subjects: 514
Study 33668050 — intervention group
Group type: EXPERIMENTAL
Intervention: MMs (15 micronutrients including IFA)
Number of subjects: 1599
Study 33668050 — intervention group
Group type: COMPARATOR
Intervention: FA (folic acid only)
Number of subjects: 1599
Study 34124856 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketogenic diet app with breath acetone biofeedback
Number of subjects: 155
Study 34124856 — intervention group
Group type: COMPARATOR
Intervention: Calorie-restricted low-fat diet app
Number of subjects: 155
Study 35810277 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone (CRO) 1 g IV + Doxycycline (DOX)
Number of subjects: 125
Study 35810277 — intervention group
Group type: COMPARATOR
Intervention: Cefixime (CFM) 800 mg oral + Doxycycline (DOX)
Number of subjects: 125
Study 35810277 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone (CRO) + Doxycycline (DOX)
Number of subjects: 125
Study 35810277 — intervention group
Group type: COMPARATOR
Intervention: Cefixime (CFM) + Doxycycline (DOX)
Number of subjects: 125
Study 33540413 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) therapy
Number of subjects: 208
Study 33540413 — intervention group
Group type: EXPERIMENTAL
Intervention: EuroQol 5-dimensions
Number of subjects: 208
Study 33540413 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-form 6-dimension medical outcome questionnaire
Number of subjects: 208
Study 33540413 — intervention group
Group type: EXPERIMENTAL
Intervention: Euro-thermometer visual analog scale
Number of subjects: 208
Study 33540413 — intervention group
Group type: EXPERIMENTAL
Intervention: Time trade-off
Number of subjects: 208
Study 33540413 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard gamble
Number of subjects: 208
Study 35483674 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg daily
Number of subjects: 60
Study 35483674 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin 100 mg daily
Number of subjects: 60
Study 34551811 — intervention group
Group type: EXPERIMENTAL
Intervention: Nudge
Number of subjects: 32
Study 34551811 — intervention group
Group type: EXPERIMENTAL
Intervention: Nudge+
Number of subjects: 32
Study 35598852 — intervention group
Group type: EXPERIMENTAL
Intervention: CT/CT angiography
Number of subjects: 190
Study 33957004 — intervention group
Group type: EXPERIMENTAL
Intervention: Nigella sativa seeds oil (2.5 ml twice daily for 8 weeks)
Number of subjects: 55
Study 32951358 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (8 mg/kg or 10 mg/kg for body weight <30 kg; 8 mg/kg for body weight ≥30 kg) administered intravenously every 4 weeks for 16 weeks, followed by random assignment to tocilizumab or placebo.
Number of subjects: 188
Study 32951358 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in part 2 of the trial).
Number of subjects: 188
Study 35461890 — intervention group
Group type: EXPERIMENTAL
Intervention: Tunnel endoscopic submucosal dissection (T-ESD)
Number of subjects: 152
Study 35461890 — intervention group
Group type: COMPARATOR
Intervention: Conventional endoscopic submucosal dissection (C-ESD)
Number of subjects: 152
Study 34063304 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT + NT
Number of subjects: 42
Study 34063304 — intervention group
Group type: EXPERIMENTAL
Intervention: NT
Number of subjects: 42